PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.

Completed

Conditions: Carcinoma
Renal Cell

Interventions: Drug: Sunitinib
Drug: Axitinib

First Posted Date: 2019-07-26

Last Posted Date: 2023-04-06

Lead Sponsor: Pfizer

Target Recruit Count: 684

Registration Number: NCT04033991

Locations: 🇬🇧
Pfizer UK, London, United Kingdom

A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

Phase 2

Completed

Conditions: Respiratory Tract Infection

Interventions: Biological: RSV vaccine
Biological: Placebo

First Posted Date: 2019-07-25

Last Posted Date: 2022-10-18

Lead Sponsor: Pfizer

Target Recruit Count: 1153

Registration Number: NCT04032093

Locations: 🇺🇸
Children's of Alabama, Birmingham, Alabama, United States
🇺🇸
Abrazo West Campus Hospital, Goodyear, Arizona, United States
🇺🇸
Cullman Clinical Research, Inc, Cullman, Alabama, United States

and more 145 locations

Effect of PF-06651600 on the Pharmacokinetics of Oral Contraceptive Steroids

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-06651600
Drug: Ethinyl estradiol (EE) and levonorgestrel(LN)

First Posted Date: 2019-07-12

Last Posted Date: 2019-11-15

Lead Sponsor: Pfizer

Target Recruit Count: 29

Registration Number: NCT04018274

Locations: 🇺🇸
Quotient Sciences Screening Office, Coral Gables, Florida, United States
🇺🇸
Quotient Sciences, Miami, Miami, Florida, United States

Comparative Analysis of Adherence and Effectiveness Outcomes Between Rheumatoid Arthritis (RA) Patients Treated With Tofacitinib Modified Release (MR)

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2019-07-12

Last Posted Date: 2024-04-03

Lead Sponsor: Pfizer

Target Recruit Count: 1057

Registration Number: NCT04018001

Locations: 🇺🇸
Pfizer, New York, New York, United States

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

Phase 1

Completed

Conditions: Hepatic Impairment
Healthy Participants

Interventions: Drug: PF-06651600 30 mg

First Posted Date: 2019-07-11

Last Posted Date: 2021-04-08

Lead Sponsor: Pfizer

Target Recruit Count: 18

Registration Number: NCT04016077

Locations: 🇺🇸
University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States

Long-Term PF-06651600 for the Treatment of Alopecia Areata

Phase 3

Active, not recruiting

Conditions: Alopecia Areata

Interventions: Drug: PF-06651600
Biological: Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine
Biological: Meningococcal (groups A, C, W-135 and Y [ACWY]) oligosaccharide diphtheria CRM197 conjugate vaccine

First Posted Date: 2019-07-05

Last Posted Date: 2025-04-23

Lead Sponsor: Pfizer

Target Recruit Count: 1052

Registration Number: NCT04006457

Locations: 🇵🇱
EMC Instytut Medyczny S.A. Przychodnia przy ul. Lowieckiej we Wroclawiu, Wroclaw, Poland
🇵🇱
Cityclinic Przychodnia Lekarsko Psychologiczna Matusiak Spółka Partnerska, Wroclaw, Poland
🇵🇱
Centrum Medyczne OPOROW, Wroclaw, Poland

and more 140 locations

Bioavailability Study of PF-06651600 Formulations in Healthy Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: PF-06651600

First Posted Date: 2019-07-02

Last Posted Date: 2019-11-01

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT04004663

Locations: 🇧🇪
Brussels Clinical Research Unit, Brussels, Be-bru, Belgium

Changes of Depression After First-year of Tofacitinib in RA Patients

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2019-06-20

Last Posted Date: 2025-04-06

Lead Sponsor: Pfizer

Target Recruit Count: 73

Registration Number: NCT03992781

Locations: 🇨🇿
Thomayerova nemocnice, Prague, Czech Republic, Czechia
🇨🇿
Rheuma s.r.o., Breclav, Czechia
🇨🇿
Revmatologie s.r.o., Brno, Czechia

and more 3 locations

A 16 Week Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: PF-06882961

First Posted Date: 2019-06-13

Last Posted Date: 2022-06-30

Lead Sponsor: Pfizer

Target Recruit Count: 412

Registration Number: NCT03985293

Locations: 🇺🇸
National Research Institute, Los Angeles, California, United States
🇺🇸
University Clinical Investigators, Incorporated, Tustin, California, United States
🇺🇸
Andres Patron D.O. P.A., Pembroke Pines, Florida, United States

and more 78 locations

IDentification of Factors Predictive of Tofacitinib's Survival in Patient With Rheumatoid Arthritis

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: Tofacitinib

First Posted Date: 2019-06-11

Last Posted Date: 2024-09-30

Lead Sponsor: Pfizer

Target Recruit Count: 314

Registration Number: NCT03981900

Locations: 🇫🇷
Cabinet Medical, Vincennes, France
🇫🇷
Centre Hospitalier D Auxerre, Auxerre, France
🇫🇷
Institut Calot Helio Marin, Berck Sur Mer, France

and more 49 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy